The advent of HAART has dramatically increased life spans of HIV-infected individuals [1, 2] . Concurrently, the incidence of AIDS-defining illnesses and opportunistic infections has declined, whereas noninfectious causes of morbidity and mortality have emerged, including an increased risk of thrombotic disease [3] [4] [5] [6] .
HIV-infected patients are two-fold to 10-fold more likely to have a venous thromboembolism (VTE) compared with the general population [7] [8] [9] . Epidemiologic studies have linked traditional risk factors including ongoing non-HIV infections and hospitalizations [7, 10] and, to a lesser extent, protease inhibitors to thrombotic events [11, 12] . Mounting evidence, however, suggests that HIVspecific factors are more heavily implicated in the pathogenesis of venous thrombotic disease [5, 7, 13] .
HIV-related chronic immune activation and inflammation may contribute to vascular dysfunction and VTE risk [14] [15] [16] [17] [18] . A wide spectrum of procoagulant abnormalities including increased levels of D-dimer, soluble thrombomodulin, P-selectin, von Willebrand factor (vWF), monocyte tissue factor expression, and anticardiolipin antibodies [19] have been observed in HIV-infected compared with uninfected individuals [15, [20] [21] [22] [23] . Many of these abnormalities correlate with the degree of immunodeficiency and concomitant presence of opportunistic infection [11, 24] . Case reports implicating co-infection with cytomegalovirus (CMV) in clot formation date back to the beginning of the HIV epidemic [24] . This may be due to impaired endothelial function and inflammation [25] of the venous vasculature [26] .
Results of the Strategies for the Management of AntiRetroviral Therapy (SMART) study showed that higher levels of pro-inflammatory cytokines and acute phase reactants [interleukin (IL)-6 and C-reactive protein (CRP), and D-dimer products of fibrinolysis], which are known to be associated with the coagulation pathway, were associated with increased all-cause mortality, cardiovascular, and opportunistic disease [27] . It is unclear whether these markers will be helpful in predicting specifically venous thrombotic disease.
In this retrospective, case-control study of HIV-infected participants with incident VTE, we hypothesized that chronic inflammation, induced by HIV infection and coexisting opportunistic disease, may contribute to the elevated risk of VTE. Exclusion criteria included experiencing a VTE prior to enrollment in NIH research protocols or prior to documented HIV seroconversion.
Methods Patient identification and definitions

Matching design
Patients with a first occurrence of VTE and cryopreserved plasma available at a pre-VTE event time point were matched 1 : 3 with HIV-infected controls by sex, age (within 5 years), and date of NIAID study enrollment (within 3 years). Controls were eligible for inclusion if they had not experienced a VTE and had cryopreserved plasma available at the time of the matching event. [15] , high-sensitivity CRP, and tissue inhibitor of metalloproteinase-1 (TIMP-1) [29] were measured by electrochemiluminescence using Human Vascular Injury I kits, Human Vascular Injury II kits, Human ProInflammatory-7 Ultra-Sensitive kits, Human Chemokine-9 Ultra-Sensitive kits, and Human TIMP-1 kits (Meso Scale Discovery, Gaithersburg, Maryland, USA).
Clinical data
Statistical methods
Nonparametric Mann-Whitney U-tests and Fisher's exact test were used for comparisons between patients with VTE and HIV-infected controls using values obtained at the time of the matching event. Continuous variables were compared using Mann-Whitney U-tests. Categorical variables were compared with Fisher's exact test. To evaluate whether relevant biomarker values were sensitive to time elapsed between measurement and time of the impending event, the relationship between biomarkers determined to be significantly associated with VTE by univariate analyses and the number of days from specimen collection to the event were evaluated by Spearman's rank-order analysis. To assess the independent association of risk factors with VTE, a logistic regression analysis was performed and included the variables that were identified on univariate analyses: active non-HIV infection, provocation, nadir CD4 cell count, one or more lifetime opportunistic infections, albumin, soluble CD14 (sCD14), D-dimer, P-selectin, thrombomodulin, vWF, SAA, CRP, IL-6, IL-8, thymus and activationregulated chemokine (TARC), TIMP-1, and hyaluronic acid. Alternative regression models, which included immunological AIDS, HIV viral load, and/or history of CMV disease, were also tested. Odds ratios for VTE were calculated for participants with median biomarker values above the 50th percentile with logistic regression. All P-values reported were two-sided. Statistical analyses were performed using JMP software (version 8.0; SAS Institute, Cary, North Carolina, USA).
Results
Clinical measures of traditional risk factors and HIV-specific characteristics Twenty-three participants experienced a first-incident VTE from a cohort of 2072 HIV-infected participants followed at the National Institutes of Health between 1995 and April of 2010. Sixty-nine HIV-infected participants with no history of VTE were matched to patients as described. Fifty-six percent of patients had a DVT (N ¼ 13), 35% had a pulmonary embolism (N ¼ 8), one had a biventricular cardiac thrombus (N ¼ 1), and one had a PVT.
Participants who had a VTE were predominantly male and the median age at which an event occurred was 47 years (Table 1) . Thirty percent of participants with a VTE and 25% of controls were black.
Participants with a VTE were four times more likely to have a history of provocation within 3 months of the matching event and a higher percentage had ongoing, non-HIV infections than controls (Table 1 ). There were no significant differences in the prevalence of IDU, hypertension, smoking, diabetes, cardiovascular disease, or malignancy between VTE patients and controls. The majority of VTE patients (91%) and their controls (85%) were antiretroviral-experienced, and the median duration of HIV infection was 9 and 10 years, respectively. There were no differences in antiretroviral regimens, cumulative antiretroviral exposure, or co-infection with hepatitis C between groups. Current or previous use of IL-2 and cumulative IL-2 exposure did not differ between the groups (data not shown).
The median CD4 nadir was 40 for VTE patients and 250 for controls (P ¼ 0.0003). Most participants in both groups had a current CD4 cell count of more than 500 cells/ml. VTE patients though were more likely to meet diagnostic criteria for immunological AIDS as determined by the most recent CD4 cell count (and/or percentage of CD4) prior to the matching event.
Prevalence of HIV viremia did not differ between the groups (39% patients vs. 35% controls, P ¼ 0.80). The majority of VTE patients had more than one lifetime opportunistic infection (52 vs. 22% in controls, P ¼ 0.008).
A significantly higher proportion of VTEpatients had a history of CMV disease. CMV viremia was more prevalent in VTE patients (13.0 vs. 0%, P ¼ 0.02). A history of Mycobacterium avium complex or tuberculosis infection was also more common in VTE patients (Table 2 ) [30] . Lower albumin was observed in VTE patients and there was a nonsignificant trend for higher platelet levels. Other laboratory variables did not differ significantly between the groups (Table 3) . P ¼ 0.03) and vWF (r ¼ À0.48, P ¼ 0.02) levels. There was no correlation with other biomarkers determined to be significant by univariate analyses.
The frequency of detectable anticardiolipin antibodies [19] immunoglobulin G (IgG) or IgM was similar in VTE patients and controls (8.7 vs. 9.8%, P ¼ 1.0).
Multivariate analysis
A multivariate regression analysis was performed that included active non-HIV infection, provocation, nadir CD4 cell count, more than one lifetime opportunistic infection, albumin, and all biomarkers determined by univariate analyses to be associated with VTE. P-selectin (P ¼ 0.002), D-dimer (P ¼ 0.01), and hyaluronic acid (P ¼ 0.009) were found to be independently associated with VTE risk. Alternative models including immunologic AIDS, HIV viral load, and CMV disease did not alter these findings.
The odds ratios of incident VTE were calculated for participants with baseline levels of P-selectin, D-dimer, or hyaluronic acid above the median. The odds ratios of VTE for participants with biomarker values exceeding the median value for all participants were 11.4 [95% confidence interval (CI) 3.1-42.3] for D-dimer, 7.6 (95% CI 2.3-24.9) for P-selectin, 1.8 (95% CI 0.7-3.8) for hyaluronic acid, and 11.2 (95% CI; 3.7-33.6) when both D-dimer and P-selectin were above the median (Table 4) .
Discussion
In this case-control study of HIV-infected patients, elevated plasma levels of P-selectin, D-dimer, and hyaluronic acid were strongly and independently linked to risk of subsequent VTE when measured prior to the event occurrence. HIV-specific risk factors including low nadir CD4 cell count, immunological AIDS, history of multiple opportunistic infections, and CMV viremia were associated with thromboembolic events, as well as ongoing, non-HIV infection and the presence of a provocation (recent hospitalization, surgery, or trauma).
In HIV-uninfected persons with a first VTE, up to half of all events are unprovoked [31] . In comparison, roughly two thirds of first-time events in our HIV-infected population occurred without an identifiable provocation.
The prevalence of non-HIV infection was high in VTE patients and their HIV-positive controls, although substantially higher in VTE patients, consistent with its known relationship to VTE in the general population. Contrary to other traditional clinical risk factors for VTE in patients without HIV, current malignancy, family history of hypercoagulability, and cardiovascular disease were not related to thrombosis in this study. The presence of a provocation or active infection in HIV-infected individuals, even in the absence of other traditional risk factors, has clinical implications for inpatient and outpatient management; extended-distance travel, surgery, hospitalization, and ongoing non-HIV infections necessitate consideration of venous thromboprophylaxis [9] .
At the time of the matching event, the vast majority of patients and controls were receiving ART with a median duration of therapy since HIV diagnosis of 6.9 and 7.3 years, respectively. Most patients had normalized CD4 cell counts (>500 cells/ml) at the time of VTE diagnosis, which is above the threshold at which current DHHS guidelines recommend starting antiretroviral treatment [32] . On the contrary, nadir CD4 cell count was significantly lower and multiple lifetime opportunistic infections were more prevalent among VTE patients than controls, despite a similar duration of HIV infection (9.3 vs. 10.5 years). Combined, these results support the hypothesis that earlier initiation of ART may modify the risk of venous thrombotic disease [3] .
HIV viremia and plasma HIV-RNA levels were not associated with VTE risk in this cohort, although other studies have reported otherwise [7, 10] . Persistent lowlevel viremia has been observed in a majority of individuals with less than 50 copies/ml [33] and chronic immune activation is evident even in patients with suppressed HIV viremia below detectable levels [34] . The contribution of viral replication to observed biomarker levels and related coagulopathies cannot, thus, be precluded in this study [27] .
Associations between D-dimer products of fibrinolysis and all-cause mortality as well as cardiovascular disease have been well established in HIV-infected and noninfected populations [27, [35] [36] [37] [38] . significant long-term predictive value in high-risk individuals and is a strategy already used to stratify risk of VTE recurrence. Furthermore, a recent meta-analysis found that timing of testing post-VTE did not affect this association [31] . In a previous report, we linked risk of CVD in HIV to elevated D-dimer levels up to 2 years prior to the index event [35] . Combined with our current findings, these data suggest that there may be clinical utility in D-dimer measurement among HIV-infected patients at elevated risk for venous and arterial thrombosis.
In addition to elevated D-dimer levels observed in HIVinfected participants with an impending VTE, several markers of inflammation (IL-6, CRP, and SAA) were also higher in patients compared with controls.
Increases in IL-6, CRP, and SAA are also related to levels of HIV-RNA [27] , risk of opportunistic infection [39] , and death [27, 40] , supporting our hypothesis that underlying inflammation, caused by both HIV [20] and non-HIV infections [41] , contributes to venous thrombotic disease. However, due to the retrospective nature of this study, temporality between biomarkers of inflammation and activation of coagulation and fibrinolytic pathways could not be determined.
A hypercoagulable state often exists among patients with HIV, including a high prevalence of detectable anticardiolipin antibodies [7] . In this study, we evaluated their role in VTE and determined that although anticardiolipin antibodies were detected more commonly in HIVinfected patients than in healthy, uninfected individuals, there was no association with VTE.
The relationship of immunodeficiency with increased coagulation factors may be due to the increased risk of opportunistic infections [7] . In support of this explanation, we found that a history of multiple lifetime opportunistic infections and advanced immunodeficiency were associated with VTE risk in the studied population. Further, CMV viremia was more prevalent among VTE patients than controls. Active CMV infection was recently associated with hypercoagulability independent of stage of HIV disease [42] . These findings suggest that CMV disease, rather than immunodeficiency alone, may result in a heightened inflammatory state leading to activation of the coagulation cascade in co-infected patients.
Another explanation for chronic inflammation in HIV may be related to the ability of HIV to cross the endothelial cell membrane, causing endothelial disruption via induction of intracellular biochemical changes and subsequent activation of inflammatory cascades and expression of endothelial cell adhesion molecules [43] .
To investigate the role of endothelial dysregulation in venous clot formation, we quantified circulating levels of P-selectin, vWF, TARC, and TIMP-1 and observed each to be significantly associated with VTE risk. A higher degree of immunodeficiency among VTE patients may in part explain these findings due to its association with impaired vascular function and endothelial inflammation in HIV disease [44, 45] .
P-selectin was found to be independently and most strongly associated with thrombosis in this cohort. Stored in endothelial cells and platelet granules, P-selectin interacts with its receptor to promote a hypercoagulable environment by inducing the generation of prothrombotic microparticles from leukocytes and upregulation of tissue factor expression on monocytes [46] [47] [48] [49] . Prospective studies in HIV-uninfected participants with malignancies have demonstrated that P-selectin is significantly elevated in patients with an impending or acute VTE. Furthermore, P-selectin has been shown to have comparable diagnostic value to D-dimer in patients with confirmed DVTs [50] .
Plasma levels of the soluble lipopolysaccharide (LPS) receptor sCD14 can be utilized as a marker of monocyte activation [51] . In our cohort, we observed a significantly higher level of sCD14 in VTE patients compared with controls, suggesting that overstimulation of monocytes from increased peripheral exposure to microbial products may contribute to a prothrombotic state in chronic HIV infection. These findings are consistent with a recent study that showed an increased proportion of monocytes expressing surface procoagulants in HIV-infected patients following LPS stimulation [15] . Contrary to expectations, we did not observe any appreciable differences in soluble TF plasma levels between groups. LPS-mediated activation of TF-dependent coagulation pathways may be confined specifically to monocyte surface TF expression.
Monocyte production of inflammatory cytokines may also be induced by hyaluronic acid degradation products through stimulation of the Toll-like receptors (TLR)-2 and TLR4 [52] . A strong indicator of liver fibrosis in HCV co-infected [53] and mono-infected [54] individuals, increased hyaluronic acid levels are also predictive of AIDS or death [55] . Although compared with controls, fewer VTE patients in our study were co-infected with HCV, overall hyaluronic acid levels were higher in VTE patients, and in a multivariate analysis, independently linked to VTE disease. These results suggest that hyaluronic acid-mediated tissue injury and inflammation may contribute to VTE risk in patients without other evidence of hepatic injury.
The limitations of our study include a relatively small number of events evaluated and the risk of increased type I error, given the considerable number of variables compared. However, in the multivariate analyses, three biomarkers retained significance: the associations of P-selectin, D-dimer, and hyaluronic acid with VTE remained strong, are biologically plausible, and relevant to other HIV-related adverse outcomes associated with their increased levels.
In summary, indices of endothelial dysfunction, coagulation, and tissue fibrosis were most strongly and independently associated with risk of venous thrombotic disease, although a history of multiple lifetime opportunistic infections, clinical CMV disease and CMV viremia, immunodeficiency, and the presence of an ongoing non-HIV infection or provocation were also related. Our findings suggest that unique risk factors in HIV-infected individuals exist that may contribute significantly to augmented risk of VTE disease. Furthermore, indices of endothelial dysfunction, coagulation, and tissue fibrosis that have been linked to morbidity and mortality in HIV infection were more strongly associated with VTE risk than other covariates examined in this study. Our results present a clinical impetus to further explore both their contributions to immunopathogenesis and the therapeutic role of modulating these biomarkers and associated inflammatory and coagulation pathways to potentially modify risk of noninfectious complications of HIV infection.
